Want to join the conversation?
$PFE and $BMY's collaboration with $PTLA on the development of drug andexanet alfa will result in $PTLA receiving an upfront payment of $15MM, potential regulatory milestones of $20MM and sales-based milestones of $70MM as well as compensation based on andexanet alfa net sales, the companies said.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?